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To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various
proatherogenic biomarkers and lipids and to investigate their relationship with subclinical
atherosclerosis in a cohort of treatment-naive HIV-infected patients.
Methods
We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive
HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B,
CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory anal-
yses and carotid ultrasound were performed at baseline and at months 12 and 24. The
parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-
associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive pro-
tein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asym-
metric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used
to assess differences in biomarkers between the study groups and over time.
Results
The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31)
and 22 controls. Age was 37 (30–43) years, and 81% were men. At baseline, the HIV-
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infected patients had a worse LDL particle phenotype and higher plasma concentration of
sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an
increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a
decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL parti-
cle size increased in group B at month 24 (p = 0.038). No changes were observed in group
A or in the healthy controls. Common carotid intima-media thickness increased in HIV-
infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of
sCD14, sCD163, and hs-CRP correlated with lipid values.
Conclusions
In treatment-naive HIV-infected patients, initiation of c-ART was associated with an
improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching
values similar to those of the controls. HIV infection was associated with progression of
carotid intima-media thickness.
Introduction
Persons with HIV (PWH) have a higher cardiovascular risk than non–HIV-infected individu-
als [1]. In addition to traditional cardiovascular risk factors, which are more frequent in the
PWH, and the deleterious effect of some antiretroviral drugs on lipid and glucose metabolism,
HIV infection itself seems to contribute greatly to overall cardiovascular risk [2]. HIV infection
may be associated with atherogenesis through at least 2 mechanisms: chronic inflammation
and immune activation that are not completely reversed by combined antiretroviral therapy
(c-ART) and disturbances in lipoprotein metabolism.
Compared with healthy individuals, PWH who are not receiving c-ART have higher plasma
levels of the inflammatory, coagulation, and immune activation biomarkers that are related to
cardiovascular disease in the general population. Viral suppression achieved with c-ART is
associated with normalization of various biomarkers, although others remain persistently high
even when c-ART is started at an early stage of infection [3–7]. In PWH, some of these bio-
markers are associated with increased subclinical carotid and coronary artery atherosclerosis
[8–10], as well as cardiovascular events and all-cause mortality [11, 12].
Lipid disorders, which are common in PWH, can be related to the infection itself or to spe-
cific antiretroviral drugs [13, 14]. An atherogenic lipoprotein phenotype has been described in
treatment-naïve PWH and is characterized by low levels of high-density lipoprotein choles-
terol (HDL-c), high triglyceride concentrations, and a predominance of small dense LDL (sd-
LDL) particles [15, 16]. LDL particles can be separated into subfractions that differ in physico-
chemical properties, such as size, charge, density, and lipid/protein composition and thus lead
to atherogenicity. Sd-LDL particles have been strongly associated with coronary artery disease
in the general population and in PWH [17, 18]. Several studies in PWH have assessed the phe-
notype of LDL particles in various scenarios [19–24]. However, to our knowledge, only one
has assessed the relationship between oxidized LDL particles and markers of inflammation
and immune activation in treatment-naïve HIV-infected patients commencing c-ART [25].
The aims of this study were to investigate the effect of HIV infection and c-ART on LDL
particle phenotype and atherogenesis-related biomarkers in a cohort of treatment-naïve HIV-
infected patients and to assess the relationship between these variables and subclinical carotid
atherosclerosis. The data we report can be added to findings published recently by our group
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on other atherogenesis-related pathways, mainly metabolism of HDL [26]. To our knowledge,
no previous studies have compared biomarkers of cardiovascular disease in treatment-naïve
HIV-infected patients starting or not starting c-ART and a healthy control group.
Materials and methods
Study design, patient population, and endpoints
We performed a prospective, observational, multicenter study of treatment-naive HIV-
infected patients recruited in 2 metropolitan hospitals in Spain (Hospital Universitari de Bell-
vitge and Hospital de Viladecans, Barcelona) and a hospital in Australia (Baker Heart and Dia-
betes Institute, Melbourne, VIC). HIV-infected patients were divided into 2 groups based on
the need to begin c-ART in accordance with European guidelines at the time the study was
designed [27]: group A, with a CD4 cell count>500 cells/μL, who did not start c-ART; and
group B, with a CD4 count<500 cells/μL, who started c-ART at the baseline visit. To be
included, patients had to be aged�18 years with HIV infection and have never received c-
ART. The exclusion criteria were diabetes mellitus, previous cardiovascular disease, secondary
dyslipidemia, malignant disease, any active infection or inflammatory disease, body mass
index (BMI) >30 kg/m2, and pregnancy. The control group consisted of healthy, HIV-nega-
tive, healthcare workers. Group A patients whose CD4 count had decreased to<500 cells/μL
were recommended to start c-ART and were not included in the follow-up analyses.
The local ethics committees approved the protocol, and written informed consent was
obtained from all participants prior to their inclusion in the study.
We recorded and compared changes in LDL particle phenotype and inflammatory bio-
marker levels in the 3 groups over a 2-year follow-up period. We investigated the association
between infection-related variables (HIV viral load and CD4 cell count) and LDL particle phe-
notype and inflammatory biomarkers and examined correlations between these variables and
subclinical atherosclerosis evaluated using carotid ultrasound.
Clinical assessment
At baseline and months 12 and 24, patients underwent a clinical assessment, laboratory analy-
ses, and carotid ultrasound. At each visit, smoking, c-ART use, and other medications (lipid-
lowering, antidiabetic, and antihypertensive agents) were recorded. The estimated overall car-
diovascular risk was calculated using the Framingham score. Blood pressure and anthropo-
metric data (height, weight, and waist and hip circumferences) were recorded.
Laboratory methods
A venous blood sample was collected (after an overnight fast), centrifuged at 4˚C, and stored
at −80ºC until analysis. All laboratory measurements were performed at a central laboratory in
Barcelona (Biochemistry Department, IIB, Sant Pau Hospital). Samples were shipped to the
central laboratory at –80ºC, and aliquots were thawed only once before the analysis; the bio-
markers analyzed have been shown to remain stable when preserved at this temperature [28].
Total cholesterol (TC), triglycerides, and glucose were measured using standard enzymatic
methods: immunoturbidometry for apolipoprotein B (Apo B) and apolipoprotein A-I (Apo
A-I) and a homogeneous direct method for HDL-c. All assays were from Roche Diagnostics
(Basel, Switzerland). LDL-c was calculated using the Friedewald formula when the triglyceride
concentration was <3.4 mmol/L or was measured after separation of lipoproteins by ultracen-
trifugation at 105,000 × g for 18 hours at 48ºC when the triglyceride level was >3.4 mmol/L.
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LDL particle phenotype was determined using gel electrophoresis in 3% polyacrylamide
tubes with a commercially available system (Lipoprint, Quantimetrix Co., Redondo Beach,
CA, USA). This method can separate 9 LDL subfractions: LDL1 to LDL3, which are large
buoyant LDL particles (lb-LDL), and LDL4 to LDL9, which are sd-LDL particles. The results
are expressed as LDL particle size (Å), percentage of sd-LDL particles, and cholesterol content
in sd-LDL and lb-LDL particles.
We followed the method of Sánchez-Quesada et al [29] to determine lipoprotein-associated
phospholipase A2 (Lp-PLA2) activity in serum (total Lp-PLA2) and in lipoproteins using
2-thio-PAF as the substrate (Cayman Chemical Company, Ann Arbor, MI, USA). We also
assessed its distribution in LDL and HDL particles. Methods for the measurement of these
non-standard lipid variables such as LDL phenotyping or measurement of Lp-PLA2 have been
validated in previous publications [22, 23, 29]
High-sensitivity C-reactive protein (hs-CRP) was quantified using an immunocolorimetry
assay (Roche Diagnostics, Basel, Switzerland) in a Cobas c501/6000 autoanalyzer. The remain-
ing biomarkers were measured using an enzyme-linked immunosorbent assay, as follows:
interleukin-6 (IL-6, eBioscience), monocyte chemoattractant protein-1 (MCP-1, eBioscience),
soluble CD14 (sCD14, Hycult Biotech), sCD163 (R&D Systems, Inc.), and asymmetric
dimethylarginine (ADMA) (BioVendor). Intra- and inter-assay variabilities were as stated by
the manufacturers.
Carotid ultrasound
High-resolution B-mode ultrasound imaging of the carotid arteries was performed using a Sie-
mens Antares Ultrasound system with a 5- to 10-MHz linear array probe. The carotid bifurca-
tion was screened for plaque starting at 3 cm proximal to the flow divider and covering up to 1
cm distal to the flow divider (internal carotid). Special care was taken at each follow-up exami-
nation to ensure that image of the bifurcation was the same as that obtained in the baseline
study. Carotid intima-media thickness (c-IMT) at the far wall of the left and right distal com-
mon carotid was measured centrally by the same investigator using the ArtWAS software
application, which enabled semiautomatic measurement of 1 cm of the distal common c-IMT
[30]. The mean of the 2 sides was used for the analysis. A common c-IMT value exceeding the
75th percentile of a reference population was considered indicative of increased cardiovascular
risk [31].
Statistical analysis
The current is a descriptive and exploratory study in which the biological variability of the ana-
lyzed variables was unknown a priori and sample size could not be estimated in advance. Cate-
gorical variables were presented as the number of cases and percentages. Continuous variables
were presented as mean and standard deviation (SD) or median and interquartile range (IQR),
depending on whether data distribution. Normality of variables was assessed with graphs
(QQ-Plot, density and standard deviations) and non-normal distributed were log-
transformed.
The Pearson correlation coefficient (r) and 95% confidence interval (CI) were calculated to
estimate the strength of the linear association between variables at baseline.
Linear mixed model with patient cluster were used to assess differences on LDL particle
phenotype and atherogenesis-related biomarkers between study groups and over time. Interac-
tion between study group and time was also assessed. The adjusted mean and 95% confidence
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interval (CI) were reported and presented in graphics. All conditions of application were
assessed.
All analyses were performed with a two-sided significance level of 0.05 and conducted with
the use of R software version 3.6.1.
Results
Participant characteristics
The study population comprised 84 participants, who were included between June 2012 and
December 2013 (62 treatment-nave HIV-infected patients [group A, n = 31 and group B,
n = 31] and 22 controls [control group]). Nine participants in group A were from the Baker
Heart and Diabetes Institute.
The baseline characteristics of the participants are shown in Tables 1 and 2. Mean (SD) age
was 37 (8.54) years, and 79.8% were men, with no differences between the groups. Significant
differences were found in several lipid and biomarker plasma levels between HIV-infected
patients and the control group. Groups A and B had lower plasma levels of TC, HDL-c, Apo
A-I, and Apo A-I/Apo B, in addition to lower LDL particle size than the control group. Plasma
levels of sCD14, LOG(sCD163), LOG(hs-PCR), and LDL-Lp-PLA2 were higher in both group
A and group B than in the control group (Figs 1–3) (Tables 1 and 2).
Group B started c-ART at the beginning of the study. The combined regimen was chosen
by the attending physician according to local practice. All patients started 2 nucleoside reverse
transcriptase inhibitors plus a protease inhibitor (n = 17), an integrase inhibitor (n = 11), a
CCR5 inhibitor (n = 2), or a non-nucleoside reverse transcriptase inhibitor (n = 1).
Table 1. Baseline characteristics of the participants.
All participants N = 83 Control group n = 22 Group A n = 30 Group B n = 31 N
Age, y 37.0 (8.54) 37.4 (8.91) 36.3 (9.06) 37.3 (7.99) 81
Male sex, N (%) 67 (79.8%) 15 (68.2%) 26 (83.9%) 26 (83.9%) 84
Time with HIV infection, months� 21.9 [6.70;50.3] - 23.1 [6.88;54.8] 19.5 [7.28;44.3] 53
HIV viral load, copies/mL� 20367 [4804;79858] - 9719 [3656;39416] 47210 [6912;129057] 58
CD4 count, cells/μL 563 (260) - 734 (193) 415 (216) 58
CD4% 31 (26–36) 19 (16–25) 58
CD4/CD8 ratio 0.75 (0.47–0.95) 0.32 (0.25–0.48) 58
BMI, kg/m2 24.4 (4.28) 23.6 (3.21) 24.6 (5.64) 24.5 (3.10) 75
Waist-to-hip ratio 0.93 (0.07) 0.90 (0.07) 0.91 (0.06) 0.96 (0.07) 65
SBP, mmHg 126 (17.2) 123 (24.5) 122 (11.0) 132 (17.3) 75
DBP, mmHg, 76.8 (10.3) 73.2 (13.3) 75.4 (8.68) 79.9 (9.61) 75
Cardiovascular risk factors
Current smoker, N (%) 28 (35.0%) 6 (31.6%) 12 (40.0%) 10 (32.3%) 80
Hypertension, N (%) 3 (3.75%) 2 (10.5%) 0 (0.00%) 1 (3.23%) 80
Family history of premature CHD, N (%) 15 (18.8%) 5 (26.3%) 5 (16.7%) 5 (16.1%) 80
Framingham risk� 3.90 [1.90;6.70] 2.55 [1.20;5.52] 3.90 [2.10;5.60] 5.15 [2.50;7.90] 71
Carotid ultrasound
Common c-IMT, mm� 0.540 [0.473;0.636] 0.552 [0.517;0.607] 0.539 [0.501;0.649] 0.520 [0.440;0.627] 75
Common c-IMT >75th percentile, N (%) 12 (16.2%) 4 (22.2%) 6 (21.4%) 2 (7.14%) 74
Carotid plaque, N (%) 5 (6.49%) 1 (4.76%) 1 (3.70%) 3 (10.3%)
Abbreviations: BMI, body mass index; c-IMT, carotid intima-media thickness; CHD, coronary heart disease; DBP, diastolic blood pressure; SBP, systolic blood pressure.
�Continuous variables expressed as median [interquartile range]; all other variables are expressed as mean (standard deviation) or N (%).
https://doi.org/10.1371/journal.pone.0237739.t001
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The CD4 cell count increased a median of 174 (62–346) cells/μL during the study in group
B, whereas no change was observed in group A. Viral load was undetectable at months 12 and
24 in 93.3% and 96.6% of participants in group B, respectively.
Because of decreases in CD4 cell count to<500 cells/μL, 3 patients in group A started c-
ART during the first year and were not included in the follow-up analyses, and 8 started during
the second year and were only included in the month 12 follow-up analysis. In addition, 6
patients in group A (3 during the first year and 3 during the second year), 1 in group B, and 2
controls were lost to follow-up. Therefore, group A included 25 and 14 patients at months 12
and 24 of follow-up, respectively.
Lipid and LDL particle phenotype changes
Lipid changes were observed only in group B. There was a significant increase in TC, HDL-c,
and Apo A-I at month 12. Total cholesterol remained stable at 24 months, and similar values
were observed between study groups. HDL-c and Apo A-I had increased further at 24 months.
The adjusted means [95% CI] of TC in group B (as indicated by the model) at baseline and 12
and 24 months were 3.9 [3.63;4.16], 4.44 [4.02;4.86], and 4.36 [3.97;4.74], respectively. The
adjusted means [95% CI] were 1.07 [0.95;1.18], 1.19 [1.09;1.29], and 1.22 [1.11;1.34] for HDL
and 1.24 [1.17;1.32], 1.33 [1.25;1.40] and 1.36 [1.26;1.45] for Apo A-I. No changes were
Table 2. Baseline laboratory characteristics of participants.
All participants N = 83 Control group n = 22 Group A n = 30 Group B n = 31 N
Lipid variables
TC, mmol/L 4.11 [3.55;4.77] 4.78 [4.08;5.23] 3.97 [3.45;4.54] 3.95 [3.33;4.44] 80
HDL-c, mmol/L 1.17 [0.89;1.41] 1.38 [1.29;1.72] 1.07 [0.86;1.39] 1.05 [0.80;1.30] 80
LDL-c, mmol/L 2.40 [1.96;3.04] 2.92 [2.24;3.32] 2.37 [1.95;2.92] 2.37 [1.86;2.60] 80
TC/HDL-c 3.49 [3.00;4.14] 3.03 [2.77;3.67] 3.77 [3.23;4.55] 3.62 [3.19;4.17] 80
Triglycerides, mmol/L 0.88 [0.72;1.12] 0.82 [0.64;1.06] 0.86 [0.72;1.34] 0.95 [0.81;1.18] 80
Apo B, g/L 0.89 [0.74;1.03] 0.94 [0.75;1.06] 0.84 [0.77;0.96] 0.89 [0.70;1.00] 80
Apo A-I, g/L 1.35 [1.14;1.51] 1.58 [1.35;1.70] 1.23 [1.13;1.41] 1.26 [1.06;1.39] 80
Apo A-I/Apo B, 1.48 [1.31;1.76] 1.74 [1.36;2.21] 1.47 [1.30;1.65] 1.44 [1.26;1.68] 80
LDL particle phenotype
LDL size, Å 272 [269;274] 273 [272;274] 272 [270;274] 270 [268;273] 81
sd-LDL particles,%, 18.4 [13.4;31.9] 15.0 [12.2;18.3] 17.9 [13.1;24.1] 29.2 [16.6;34.6] 78
Cholesterol in sd-LDL, mmol/L, 0.49 [0.29;0.74] 0.36 [0.30;0.57] 0.49 [0.24;0.64] 0.61 [0.34;0.82] 78
Cholesterol in lb-LDL, mmol/L, 1.80 [1.46;2.33] 2.39 [1.64;2.78] 1.93 [1.48;2.29] 1.64 [1.30;1.96] 78
Biomarkers
Total Lp-PLA2 activity, μmol/min�mL 18.8 [16.1;21.3] 17.9 [15.2;20.2] 18.9 [16.7;20.9] 19.3 [16.7;22.2] 83
LDL-Lp-PLA2 (%), 62.1 [57.6;66.1] 57.6 [54.6;62.6] 62.6 [59.8;66.0] 62.2 [59.2;67.5] 83
sCD14, μg/mL 1.97 [1.66;2.31] 1.70 [1.54;1.95] 1.86 [1.66;2.13] 2.36 [2.10;3.10] 79
sCD163, ng/mL 478 [284;904] 260 [185;453] 500 [334;710] 836 [423;1195] 80
ADMA, μmol/L 0.52 [0.44;0.58] 0.52 [0.45;0.60] 0.45 [0.38;0.53] 0.54 [0.51;0.57] 77
IL-6, pg/mL 1.13 [0.89;1.36] 0.93 [0.73;1.30] 1.16 [0.98;1.44] 1.13 [0.93;1.32] 80
hs-CRP, mg/L 0.90 [0.50;1.85] 0.45 [0.30;0.80] 1.25 [0.78;2.47] 1.25 [0.60;3.43] 80
MCP-1, pg/mL 77.8 [60.9;89.9] 74.8 [51.0;86.4] 78.9 [62.1;92.2] 77.9 [66.1;89.9] 78
Abbreviations: ADMA, asymmetric dimethylarginine; Apo, apolipoprotein; HDL-c, high density lipoprotein-cholesterol; hs-CRP, high-sensitivity C-reactive protein;
IL-6, interleukin-6; lb-LDL, large buoyant low-density lipoprotein; LDL-c, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2;
MCP-1, monocyte chemoattractant protein-1; sd-LDL, small dense low-density lipoprotein; TC, total cholesterol. Continuous variables are expressed as median
[interquartile range].
https://doi.org/10.1371/journal.pone.0237739.t002
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observed in group B for LDL-c, Apo B, TC/HDL-c, the Apo A-I/Apo B ratio, or triglycerides.
There were no changes in any of the lipid parameters in group A or in the control group (Figs
1, 2 and 3) (S1 Table of S1 Data).
LDL particle size and cholesterol content in lb-LDL particles improved in group B at
month 24. According to the model, the adjusted means [95%CI] at baseline and 12 and 24
months in group B were 269.86 [268.4;271.31], 270.46 [268.71;272.21], and 271.53
[270.54;272.51], respectively, for LDL particle size and 1.66 [1.45;1.87], 1.87 [1.61;2.13], and
1.98 [1.71;2.25] for cholesterol content in lb-LDL. There were no changes in group A or in the
control group. At month 24, there were no significant differences in LDL phenotype between
the 3 study groups (Fig 2) (S2 Table of S1 Data).
We carried out a correlation analysis with lipid variables including all participants. At base-
line, LDL particle size correlated with several lipid variables and BMI (r[95% CI] = –0.261 [–
0.463; –0.033]) (Table 2). No correlations were found between lipid variables and HIV viral
load or CD4 cell count.
Fig 1. Mean adjusted for group, time, and interaction between group and time and 95% CI in lipid parameters from baseline to months 12 and 24. �Mean
adjusted for group, time, and interaction between group B and time. ��Mean adjusted for group and time. In TC, the interaction between time and group was
statistically significant for group B at 12 months (p = 0.002). In HDL-c and APO A-1, the interaction was statistically significant for group B at 12 months (p = 0.003 and
0.049, respectively) and 24 months (p = 0.001 and 0.008, respectively). Moreover, for all 3 lipid parameters, differences at baseline were statistically significant for group
A compared with the control group (p = 0.03,<0.001, and<0.001, respectively) and group B compared with the control group (p = 0.004,<0.001, and<0.001,
respectively). In the case of LDL-c and Apo A-I/Apo B, differences at baseline were statistically significant in group B compared with the control group (p = 0.019 and
0.021); baseline differences in group A compared with the control group were statistically significant only for Apo A-I/Apo B (p = 0.017). Abbreviations: TC, total
cholesterol; HDL-c, high-density lipoprotein cholesterol.
https://doi.org/10.1371/journal.pone.0237739.g001
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Changes inflammatory biomarkers
Changes were observed only in group B, with a significant decrease in sCD14 and in LOG
(sCD163) at 12 months and a further decrease at 24 months. In line with the model, the
adjusted means [95% CI] in group B at baseline and 12 and 24 months were 2.57 [2.27;2.87],
2.05 [1.85;2.25], and 2.03 [1.81;2.26] for sCD14 plasma levels and 6.57 [6.32;6.81], 5.93
[5.66;6.19], and 5.98 [5.77;6.18] for LOG(sCD163). During the study period, no changes were
recorded for hs-CRP, which remained higher in group B at month 24 (Fig 3). No changes in
IL-6, ADMA, or MCP-1 were observed in any group at 12 and 24 months. Similar values of
IL-6, ADMA, and MCP-1 between study groups were expected at 12 and 24 months (S2
Table of S1 Data).
Total Lp-PLA2 remained largely unchanged in all 3 groups during the study, although a sig-
nificant decrease in LDL-Lp-PLA2 was observed at 24 months. Consistent with the model, the
adjusted means [95% CI] for LDL-Lp-PLA2 in group B at baseline and 12 and 24 months were
62.79 [60.59;64.99], 62.82 [60.63;65.00], and 58.24 [55.41;61.07] (Fig 3) (S2 Table of S1 Data).
A correlation analysis based on CD4 cell count, HIV viral load, and the lipid variables was
carried out at baseline. sCD14, sCD163, and hs-CRP levels correlated with those of several
lipid variables (TC, HDL-c, LDL-c, Apo A-I, TC/HDL-c, Apo A-I/Apo B, and triglycerides).
Various correlations were also found between plasma biomarkers (Table 3).
Changes in carotid intima-media thickness, anthropometric measures, and
cardiovascular risk score
At baseline, common c-IMT was thicker in the control group than in group B (Table 1 and Fig
4). There was a significant increase in common c-IMT in group B at 24 months (p = 0.048);
the difference was almost significant in group A (p = 0.53). The adjusted means [95%CI] for c-
Fig 2. Mean adjusted for group, time, and interaction between group and time and 95% CI in LDL particle phenotype parameters from baseline to months 12 and
24. �Mean adjusted for group, time, and interaction between group B and Time. In LDL size and cholesterol content in lb-LDL particles, the interaction between time
and group was statistically significant for group B at 24 months (p = 0.038 and 0.009, respectively). Moreover, in both variables, the differences at baseline were
statistically significant for group B compared with the control group (p = 0.011 and 0.001, respectively); baseline differences in group A compared with the control group
were statistically significant only for LDL size (p = 0.049). Abbreviations: LDL, low-density lipoprotein cholesterol; lb-LDL, large buoyant LDL particles.
https://doi.org/10.1371/journal.pone.0237739.g002
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IMT in group B were 0.504 [0.45;0.558], 0.522 [0.448;0.586], and 0.557 [0.501;0.614]. No
changes were recorded in the percentage of participants with common c-IMT over the 75th
percentile.
Fig 3. Mean adjusted for group, time, and interaction between group and time and 95% CI in plasma biomarkers from baseline to months 12 and 24. �Mean
adjusted for group, time, and interaction between Group B and time. ��Mean adjusted for group and time. In sCD14 and LOG(sCD163), the interaction between group
and time was statistically significant for group B at 12 months (p<0.001 and<0.001, respectively) and 24 months (p<0.001 and<0.001, respectively). Moreover,
differences at baseline were statistically significant in LOG(sCD163) and sCD14 for group A compared with the control group (p = 0.001 and p = 0.038 respectively) and
group B compared with the control group (p<0.001 and p<0.001 respectively). In LDL-Lp-PLA2, the interaction between time and group was statistically significant for
group B at 24 months (p<0.001); differences at baseline were statistically significant for groups A and B compared with the control group (p = 0.048 and p = 0.01,
respectively). In LOG(hs-CRP), the differences at baseline were statistically significant for groups A and B compared with the control group (p = 0.007 and p = 0.002,
respectively). Abbreviations: hs-CRP, high-sensitivity C-reactive protein; LDL-Lp-PLA2, lipoprotein-associated phospholipase A2.
https://doi.org/10.1371/journal.pone.0237739.g003
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At baseline, common c-IMT correlated with age (r[95% CI], 0.387 [0.174;0.565]), Framing-
ham score (Log) (r[95% CI], 0.362 [0.133;0.554]), TC (r[95% CI], 0.257 [0.029;0.46]), LDL-c (r
[95% CI], 0.289 [0.063;0.487]), and BMI (r[95% CI], 0.285 [0.052;0.489]), but not with bio-
markers, HIV viral load, or CD4.
Cardiovascular risk measured by Framingham score (LOG) at baseline was similar in all 3
study groups and did not change significantly during the study period.
A sensitivity analysis revealed a non statistically significant interaction between patients
with a regimen containing a protease inhibitor or not (S3 Table of S1 Data).
Discussion
In this study, we assessed biological and ultrasound biomarkers of atherogenesis in treatment-
naive HIV-infected patients who initiated or did not initiate c-ART and in a healthy control
group over a 2-year follow-up period. The study was designed before the recommendation
that all PWH should start c-ART regardless of CD4 cell count. Therefore, we had a unique
opportunity to assess a series of atherogenesis-related variables in a group of treatment-naive
HIV-infected patients and compare the results with those of patients starting c-ART. Our
main finding was that levels of inflammatory and immune activation markers were higher and
the lipid profile more unfavorable in treatment-naive patients than in controls. In addition,
starting c-ART was associated with decreased levels of some biomarkers and an improvement
in LDL particle phenotype and some lipids. All of these biomarkers reached levels similar to
those of the controls, with the exception of hs-CRP, which remained higher. Finally, c-ART
could not prevent an increase in common c-IMT, although the percentage of participants with
subclinical atherosclerosis remained low.
A pro-atherogenic lipid pattern mediated by cytokine dysregulation in chronic inflamma-
tion and infection has previously been described in naive HIV-infected patients [13–16].
Table 3. Correlations between plasma biomarkers, lipids, and HIV status at baseline.
LDL size Total Lp-PLA2 IL-6 sCD14 LOG(sCD163) LOG(hs-CRP)
LOG(HIV viral load) 0.02 [-0.24;0.28] -0.05 [-0.3;0.22] 0.09 [-0.18;0.35] -0.04 [-0.31;0.23] 0.2 [-0.07;0.44] 0.23 [-0.04;0.47]
CD4 count 0.12 [-0.14;0.37] -0.05 [-0.31;0.21] 0.31 [0.05;0.53] -0.02 [-0.29;0.26] -0.24 [-0.48;0.03] -0.13 [-0.39;0.14]
LOG(CD4/CD8) 0.2 [-0.06;0.44] -0.24 [-0.47;0.02] 0.29 [0.02;0.52] -0.02 [-0.29;0.25] -0.26 [-0.49;0.01] -0.15 [-0.4;0.13]
TC -0.01 [-0.23;0.22] 0.11 [-0.11;0.32] -0.1 [-0.32;0.12] -0.02 [-0.25;0.21] -0.31 [-0.5;-0.09] -0.24 [-0.44;-0.02]
HDL-c 0.43 [0.22;0.59] -0.34 [-0.52;-0.13] -0.17 [-0.38;0.06] -0.1 [-0.32;0.13] -0.3 [-0.49;-0.09] -0.3 [-0.49;-0.09]
LDL-c 0.13 [-0.09;0.34] 0.25 [0.03;0.44] -0.13 [-0.34;0.1] 0.01 [-0.21;0.24] -0.29 [-0.48;-0.08] -0.22 [-0.42;0]
TC/HDL-c -0.54 [-0.68;-0.36] 0.47 [0.27;0.62] 0.08 [-0.15;0.29] 0.07 [-0.16;0.29] 0.11 [-0.11;0.32] 0.18 [-0.04;0.38]
LOG (triglycerides) -0.69 [-0.79;-0.55] 0.16 [-0.06;0.37] 0.13 [-0.1;0.34] 0.05 [-0.18;0.27] 0.12 [-0.1;0.33] 0.19 [-0.03;0.39]
Apo B -0.19 [-0.39;0.04] 0.3 [0.09;0.49] -0.1 [-0.31;0.13] 0.04 [-0.19;0.26] -0.22 [-0.42;0] -0.17 [-0.37;0.06]
Apo A-I 0.21 [-0.01;0.41] -0.17 [-0.37;0.05] -0.08 [-0.29;0.15] -0.2 [-0.41;0.03] -0.34 [-0.52;-0.13] -0.28 [-0.47;-0.07]
Apo A-I/Apo B 0.29 [0.07;0.48] -0.42 [-0.59;-0.22] 0.04 [-0.18;0.26] -0.13 [-0.34;0.1] -0.09 [-0.3;0.13] -0.09 [-0.3;0.14]
LDL size – -0.19 [-0.39;0.03] -0.04 [-0.27;0.18] -0.14 [-0.35;0.09] -0.09 [-0.31;0.13] -0.24 [-0.44;-0.02]
Total Lp-PLA2 – – 0 [-0.22;0.23] -0.03 [-0.26;0.19] -0.05 [-0.27;0.18] 0.03 [-0.19;0.24]
IL-6 – – – 0.01 [-0.22;0.24] 0.28 [0.06;0.47] 0.2 [-0.02;0.41]
sCD14 – – – – – 0.48 [0.29;0.63]
LOG(sCD163) – – – – – 0.09[-0.14;0.32]
Abbreviations: Apo, apolipoprotein; HDL-c, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LDL-c, low-density
lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2; MCP-1, monocyte chemoattractant protein-1; sd-LDL, small dense low-density lipoprotein;
TC, total cholesterol. No significant correlations were observed for MCP-1 or asymmetric dimethylarginine. Therefore, they are not shown in the table.
https://doi.org/10.1371/journal.pone.0237739.t003
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Consistent with these findings and compared with the controls, the treatment-naive patients
in our study had lower HDL-c levels, a tendency toward a higher TC/HDL-c ratio, and a more
unfavorable LDL particle phenotype (lower LDL particle size and percentage of lb-LDL parti-
cles). sd-LDL particles are more atherogenic owing to various mechanisms: they are more
avidly taken up by macrophages and are more susceptible to oxidative modification, they have
a greater propensity for transport into the arterial subendothelial space, and they have greater
potential for binding to arterial wall proteoglycans than lb-LDL particles [17].
Our findings point to a relationship between a proatherogenic lipid pattern and immune
activation and inflammation. At baseline, the highest sCD163, sCD14, and hs-CRP biomarker
levels were associated with the lowest TC and HDL-c levels and the highest TC/HDL and tri-
glyceride levels. Recent reviews of the relationship between lipid homeostasis, inflammation,
and immune activation related to microbial translocation showed that, on the one hand, the
consequences of microbial translocation (such as increased lipopolysaccharide level) can lower
expression of ATP-binding cassette transporters, thus reducing reverse cholesterol transport
from the arterial wall to HDL particles. On the other hand, immune activation can also
enhance the activity of reactive oxygen species and enzymes such as Lp-PLA2, thereby render-
ing LDL and HDL particles more pro-inflammatory [32, 33]. Data on the association between
immune activation, inflammation, and lipids in PWH are scarce [10, 25, 34, 35]. sCD14,
sCD163, and hs-CRP have been associated with oxidized forms of LDL and HDL in treat-
ment-naive patients and after initiation of c-ART [25].
Fig 4. Mean adjusted for group, time, and interaction between group and time and 95% CI in common c-IMT
from baseline to months 12 and 24. The interaction between group and time was statistically significant at 24 months
for group B (p = 0.048) and almost significant for group A (p = 0.053). The interaction was statistically significant for
group B compared with the control group (p = 0.015). Abbreviations: c-IMT, carotid intima-media thickness.
https://doi.org/10.1371/journal.pone.0237739.g004
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In our study, initiation of c-ART was associated with an increase in plasma lipid concentra-
tions to levels similar to those of the controls, which can be considered a return to a “healthy”
state [25]. LDL particle phenotype also improved in patients starting c-ART, despite the non-
significant increase in triglycerides, a key determinant of LDL particle size and density. Consis-
tent with the results of the present study, our group previously reported an improvement in
LDL particle phenotype with initiation of ritonavir-boosted darunavir, whereas phenotype
worsened in patients receiving ritonavir-boosted atazanavir, in association with a greater
increase in triglyceride levels [23]. In contrast, in a study assessing the characteristics of LDL
particles in treatment-naïve patients starting atazanavir/ritonavir, darunavir/ritonavir, or ralte-
gravir plus tenofovir-emtricitabine, Kelesidis et al [24] found a decrease in LDL particle num-
bers only with raltegravir and no changes in LDL particle size in any treatment arm. The
laboratory methods used by Kelesidis et al differed from ours and may thus explain the con-
trasting findings. In summary, HIV infection is related to a pro-atherogenic LDL particle phe-
notype that improves after initiation of c-ART, reaching values similar to those of controls
despite increases in the levels of traditional lipid parameters, which may be associated with the
improvement in immune activation observed in our study.
We observed a beneficial effect of suppressive c-ART on biomarkers of inflammation
(LDL-Lp-PLA2) and immune activation (sCD14 and sCD163), which reached concentrations
similar to those of the controls. Nonetheless, some degree of inflammation persisted, as evi-
denced by the continuously elevated levels of hs-CRP. Previous studies have also shown
improvements in biomarkers after suppressive c-ART, although continuously high plasma
concentrations of some biomarkers of inflammation (hs-CRP, IL-6, TNF) and immune activa-
tion (sCD14) have been reported by several authors [3–6, 36]. Recovery of CD4 cell counts
and, to a lesser extent, control of HIV viral load have been associated with a decrease in some
biomarkers of inflammation and immune activation [5]. It has been amply demonstrated that
c-ART alone cannot normalize the plasma levels of all biomarkers. Other factors, such as intes-
tinal microbial translocation, persistent viral replication, and co-infections (eg, by hepatitis
virus and cytomegalovirus), which are not reverted by c-ART, are thought to contribute to per-
sistence of inflammation [3, 5, 7].
Carotid-IMT and plaque are predictors of future cardiovascular events in the general popu-
lation and have been used as surrogate markers of cardiovascular disease [37]. At baseline in
our study, c-IMT was higher in the healthy control group and was associated with traditional
cardiovascular risk factors (age and Framingham score) but not with HIV-specific factors.
While common c-IMT has been assessed in naive HIV-infected patients in various studies
[38–42], only 2 included a healthy control group, and no differences between HIV or healthy
groups were found [39,42]. Hileman et al [39] reported a similar increase in common c-IMT
in both treatment-naïve HIV-infected patients without c-ART and healthy controls followed
over a period of 2 years; moreover, this increase was independently associated with hs-CRP. In
contrast, we recorded a greater increase in common c-IMT in HIV-infected patients who
started or did not start c-ART, but not in the control group, suggesting that HIV infection itself
plays a role that may be mediated by hs-CRP, which remained higher in HIV-infected patients.
It is noteworthy that the percentage of participants with c-IMT over the 75th percentile, which
was associated with increased cardiovascular risk, did not change during the study.
Our study has several major limitations. The small sample size at baseline and the with-
drawal of some participants in group A (mainly because of initiation of c-ART due to disease
progression and, less frequently, because of loss to follow-up) decrease the power of the study
and may introduce bias in the results. Moreover, variability in the repeated measures of c-IMT
could hamper interpretation of the results. Therefore, findings for c-IMT must be interpreted
with caution, mainly in group A. Nonetheless, the fact that significant changes were recorded
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confers validity to the study. The prospective design and inclusion of treatment-naïve HIV-
infected patients and healthy controls provided the opportunity to study the effect of HIV
infection and c-ART on various biomarkers and on subclinical atherosclerosis. The use of dif-
ferent types of c-ART with specific effects on lipids, biomarkers, and even c-IMT [4, 24] may
have confounded the results; however, a sensitivity analysis among patients receiving and not
receiving protease inhibitors did not reveal differences in the variables analyzed. At baseline
there were several differences in the variables analyzed between the control group and the two
HIV-infected groups, related mainly with the own HIV-infection. The population included
was young and predominantly male, thus precluding generalization of the results to older
patients and women.
Conclusions
In conclusion, this study shows that c-ART normalizes the lipid profile and improves LDL par-
ticle phenotype and immune activation, although some degree of inflammation persists. How-
ever, c-ART was unable to prevent progression of common c-IMT. As c-ART alone did not
fully normalize the values of biomarkers of inflammation, additional strategies are needed to
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